Metabolic Health
MOTS-c Injection
A mitochondrial-derived peptide studied in early research for its potential role in insulin sensitivity and exercise metabolism — an emerging area of peptide research rather than a proven metabolic treatment.
This is a compounded preparation made by a licensed pharmacy. It is not FDA-approved, and it is prescribed only when a licensed provider determines it is appropriate for you.
Already know this is what you want? The second option books the appointment straight away. Not sure yet? See the labs first.
Your consult is free. We will not prescribe this, or anything, before a clinician has spoken with you. Final cost depends on the form and dose prescribed.
Mechanism
Mitochondrial signal, still early.
MOTS-c is a peptide encoded within mitochondrial DNA, discovered through research into how mitochondria communicate with the rest of the cell. Preclinical studies have explored its relationship to insulin sensitivity and metabolic regulation.
Some researchers have also studied MOTS-c in connection with exercise capacity, prompting interest in it among patients focused on metabolic and fitness goals.
It is generally prescribed as a cycled protocol alongside diet and exercise rather than as a standalone solution for weight or metabolic concerns.
Protocol
How treatment usually runs.
A typical schedule. Yours is set by your clinician, and adjusted as you go.
| Phase | Weeks | Typical | Purpose |
|---|---|---|---|
| Start | 1–2 | Low dose, several times per week | Subcutaneous injection; not necessarily daily. |
| Build | 3–6 | Standard dose, 3–5x weekly | Often paired with structured exercise. |
| Taper / Reassess | 7–8 | Continued or cycled off | Reviewed with your provider around 6–8 weeks. |
What to expect
Honestly, over time.
Early phase
No reliably reported early subjective changes; effects are not immediate.
Monitoring phase
Any metabolic changes are best tracked with labs and body composition, not how you feel.
Cycle review
Your provider reassesses continuation based on objective markers.
Evidence
What the research shows.
Research on MOTS-c is largely preclinical and based on animal models and small early human studies; there is no large controlled human trial establishing its effect on insulin sensitivity, exercise performance or weight in people. It should not be treated as an established metabolic or weight-loss therapy.
Results vary. Clinical trial results apply only to the FDA-approved branded medication specifically identified and do not apply to compounded medications. All medications must be prescribed by a licensed provider based on medical necessity.
Safety and eligibility
Your consult and labs screen for all of the following.
- Do not use if you are pregnant or breastfeeding, or have an active, unmanaged endocrine disorder without your provider's guidance.
- Tell your provider about diabetes or other blood sugar-affecting conditions and any medications that affect insulin or metabolism.
- Common side effects include injection-site reaction and, less commonly, flushing or mild lightheadedness.
- Not FDA-approved for this use — prescribed at your provider's discretion.
FAQ
MOTS-c Injection questions.
MOTS-c is studied in early research for a possible role in insulin sensitivity and exercise metabolism. It's an emerging area of peptide research, not an established treatment for diabetes or weight loss.
Not necessarily. Unlike sleep or recovery peptides, metabolic changes from MOTS-c (if any) are better tracked through labs and body composition over weeks, not subjective day-to-day feeling.
It's typically injected a few times a week rather than daily, often alongside a structured exercise program, with your provider reviewing the protocol every several weeks.
Related
Often part of the same plan.
NAD+ Injection
Subcutaneous injection
